Compare C2N Diagnostics vs SYNAPS Dx
Customers evaluate the quality of C2N Diagnostics's products using the following success metrics.
Overview
C2N Diagnostics is 17 yrs old and is based in United States.
C2N Diagnostics is a molecular diagnostics company. It offers sensitive mass spectrometry-based identification, quantification, and monitoring of proteins, protein fragments, and other biomolecules implicated in human neurological diseases. The company was founded in 2007 and is based in Saint Louis, Missouri.
SYNAPS Dx is 8 yrs old and is based in United States.
SYNAPS Dx is a company focused on Alzheimer's Disease diagnostics within the healthcare sector. The company provides scientific data to healthcare professionals to identify Alzheimer's Disease and distinguish it from other forms of dementia. The primary customers of SYNAPS Dx are healthcare professionals and institutions within the healthcare industry. It was founded in 2016 and is based in Rockville, Maryland.
Demo Video
Leadership
Joel Braunstein (Founder, Chief Executive Officer)
Frank Amato (Chief Executive Officer, President)
Investors
GHR Foundation, Alzheimer's Drug Discovery Foundation
Semler Scientific
Product
Information not available because C2N Diagnostics has not claimed their profile.
Work for C2N Diagnostics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for C2N Diagnostics?
Claim your profile now.
Why SYNAPS Dx beats C2N Diagnostics
Benefits
- Turnaround time in processing a 3mm skin sample and giving the doctor a read out of the test.
Products
DISCERN
A three assay highly accurate test for diagnosing Alzheimer's Disease.
Customers
Known Partners
Why They Buy